UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Orchard Therapeutics Plc

(Name of Issuer)

American Depository Shares

(Title of Class of Securities)

68570P101

(CUSIP Number)

December 15, 2022

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

x Rule 13d-1(c)

□ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 7

CUSIP No. 68570P101

			CUSIP No. 68570P101			
1	NAMES OF REPORTING PERSONS					
⊥	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	Zontroo Invoctore	nto I imital				
	Zentree Investments Limited CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)					
2	CHECK ITE AP	TRUPRIAL	(a) □ (b) □			
3	SEC USE ONLY					
5						
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	The Cayman Islands					
		5	SOLE VOTING POWER			
		J				
			-0-			
NUMBER OF		6	SHARED VOTING POWER			
SHARES BENEFICIAI	IV		12,918,118			
OWNED BY		7	SOLE DISPOSITIVE POWER			
EACH REPO		1				
PERSON WI	TH:		-0-			
		8	SHARED DISPOSITIVE POWER			
			12,918, 118			
	AGGREGATE A	MOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON			
9						
	12,918, 118					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)					
11			RESENTED BY AMOUNT IN ROW (9)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	10.197%					
12						
14						
	00					

Page 2 of 7

		CUSIP No. 68570P101				
NAMES OF REPORTING PERSONS						
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
Pichard Magida	c					
	(a) 🗆					
CHECK HE A	$(a) \square$					
SEC USE ONLY						
CITIZENSHIP (OR PLACE ()F ORGANIZATION				
4 CITIZENSHIP OR PLACE OF ORGANIZATION						
British						
	5	SOLE VOTING POWER				
		0				
F	C	-				
1	6					
		12,918,118				
	7	SOLE DISPOSITIVE POWER				
		0				
	0	-				
	ð					
		12,918,118				
AGGREGATE A	AMOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON				
12 918 118						
	F THE AGG	REGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHAI	RES (see instructions)			
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
10.197%						
	ORTING PEF	SON (see instructions)				
IN						
	I.R.S. IDENTIF	I.R.S. IDENTIFICATION NO Richard Magides CHECK THE APPROPRIAT SEC USE ONLY CITIZENSHIP OR PLACE O British CITIZENSHIP OR PLACE O British 5 F 6 CITIZENSHIP OR PLACE O British 5 AGGREGATE AMOUNT BI 12,918,118 CHECK BOX IF THE AGGH D PERCENT OF CLASS REPH 10.197% TYPE OF REPORTING PER	NAMES OF REPORTING PERSONS LR.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Richard Magides CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION British F ILY 7 SOLE VOTING POWER 12,918,118 7 SOLE DISPOSITIVE POWER 12,918,118 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,918,118 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHAIL PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.197% TYPE OF REPORTING PERSON (see instructions)			

Page 3 of 7

Item 1(a). Name of Issuer:

Orchard Therapeutics Plc

Item 1(b). Address of Issuer's Principal Executive Offices:

108 Cannon Street London, United Kingdom

Item 2(a). Name of Person Filing:

Zentree Investments Limited Richard Magides

Item 2(b). Address of Principal Business Office or, if none, Residence:

Zentree Investments Limited 65 Chulia Street #45-04 OCBC Centre Singapore 049513 Citizenship: The Cayman Islands

Richard Magides 65 Chulia Street #45-04 OCBC Centre Singapore 049513 Citizenship : British

Item 2(c). Citizenship:

Zentree Investments Limited Citizenship The Cayman Islands Richard Magides: Citizenship British

Item 2(d). Title of Class of Securities:

American Depository Shares

Item 2(e). CUSIP Number: 68570P101

Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) \Box Broker or dealer registered under Section 15 of the Act;
- (b) \Box Bank as defined in Section 3(a)(6) of the Act;
- (c) \Box Insurance company as defined in Section 3(a)(19) of the Act;
- (e) \Box An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) \Box An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) \Box A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) 🗆 A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b) (1)(ii)(J), please specify the type of institution:

Page 4 of 7

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:

As of the close of business on December 15, 2022, Zentree Investments Limited ("Zentree") and Richard Magides beneficially owned a total of 12,918,118 American Depository Shares of the Issuer, representing 12,918,118 ordinary shares nominal value £0.10 per share. Of this amount Zentree owns 5,779,983 shares and Mr. Magides owns 7,138,135 shares. Richard Magides is the director of Zentree Investments Limited and may be deemed to have shared voting control and investment discretion over securities owned by Zentree.

(b) Percent of Class:

As of the close of business on December 15, 2022 Zentree and Mr. Magides may be deemed to have beneficially owned 12,918,118 American Depository Shares of the Issuer outstanding (see Item 4(a) above). This percentage was calculated based on 126,689,717 ordinary shares, nominal value £0.10 per share, outstanding as of November 10, 2022 as per the Issuer's Form 10-Q for the quarter ended September 30, 2022.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

-0-

(ii) Shared power to vote or to direct the vote

12,918,118 (See Item 4(a))

(iii) Sole power to dispose or to direct the disposition of

-0-

(iv) Shared power to dispose or to direct the disposition of

12,918,118 (See Item 4(a))

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Page 5 of 7

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 19, 2022

Zentree Investments Limited

/s/ Richard Magides Name: Richard Magides Title: Director

Page 7 of 7